APOL1-Mediated Kidney Disease.
| dc.contributor.author | Hopper, Timothy | |
| dc.contributor.author | Olabisi, Opeyemi A | |
| dc.date.accessioned | 2024-06-01T15:28:13Z | |
| dc.date.available | 2024-06-01T15:28:13Z | |
| dc.date.issued | 2024-04 | |
| dc.description.abstract | <jats:p>This JAMA Insights reviews the origin of <jats:italic>APOL1</jats:italic> high-risk genetic variants, defines APOL1-mediated kidney disease, and discusses recommendations for screening and management.</jats:p> | |
| dc.identifier | 2818065 | |
| dc.identifier.issn | 0098-7484 | |
| dc.identifier.issn | 1538-3598 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | American Medical Association (AMA) | |
| dc.relation.ispartof | JAMA | |
| dc.relation.isversionof | 10.1001/jama.2024.2667 | |
| dc.rights.uri | ||
| dc.subject | Apolipoprotein L1 | |
| dc.subject | Humans | |
| dc.subject | Animals | |
| dc.subject | Kidney Diseases | |
| dc.subject | Mice | |
| dc.title | APOL1-Mediated Kidney Disease. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Olabisi, Opeyemi A|0000-0003-0886-7605 | |
| pubs.begin-page | 1668 | |
| pubs.end-page | 1669 | |
| pubs.issue | 19 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Medicine | |
| pubs.organisational-group | Medicine, Nephrology | |
| pubs.organisational-group | Duke Molecular Physiology Institute | |
| pubs.publication-status | Published | |
| pubs.volume | 331 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- APOL1-Mediated Kidney Disease_published.pdf
- Size:
- 188.29 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version